PL1937671T3 - Związki benzimidazolotiofenowe jako inhibitory plk - Google Patents

Związki benzimidazolotiofenowe jako inhibitory plk

Info

Publication number
PL1937671T3
PL1937671T3 PL06813896T PL06813896T PL1937671T3 PL 1937671 T3 PL1937671 T3 PL 1937671T3 PL 06813896 T PL06813896 T PL 06813896T PL 06813896 T PL06813896 T PL 06813896T PL 1937671 T3 PL1937671 T3 PL 1937671T3
Authority
PL
Poland
Prior art keywords
thiophene compounds
plk inhibitors
benzimidazole thiophene
benzimidazole
plk
Prior art date
Application number
PL06813896T
Other languages
English (en)
Inventor
Mui Cheung
Kyle Allen Emmitte
James Michael Salovich
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of PL1937671T3 publication Critical patent/PL1937671T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL06813896T 2005-09-06 2006-08-28 Związki benzimidazolotiofenowe jako inhibitory plk PL1937671T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US71433705P 2005-09-06 2005-09-06
US78624406P 2006-03-27 2006-03-27
EP06813896A EP1937671B1 (en) 2005-09-06 2006-08-28 Benzimidazole thiophene compounds as plk inhibitors
PCT/US2006/033683 WO2007030361A2 (en) 2005-09-06 2006-08-28 Benzimidazole thiophene compounds as plk inhibitors

Publications (1)

Publication Number Publication Date
PL1937671T3 true PL1937671T3 (pl) 2010-05-31

Family

ID=37631488

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06813896T PL1937671T3 (pl) 2005-09-06 2006-08-28 Związki benzimidazolotiofenowe jako inhibitory plk

Country Status (28)

Country Link
US (2) US7595330B2 (pl)
EP (1) EP1937671B1 (pl)
JP (1) JP5002597B2 (pl)
KR (1) KR20080047585A (pl)
AR (1) AR055616A1 (pl)
AT (1) ATE452132T1 (pl)
AU (1) AU2006287766B2 (pl)
BR (1) BRPI0615668A2 (pl)
CA (1) CA2621879A1 (pl)
CR (1) CR9786A (pl)
CY (1) CY1109916T1 (pl)
DE (1) DE602006011192D1 (pl)
DK (1) DK1937671T3 (pl)
EA (1) EA014111B1 (pl)
ES (1) ES2337929T3 (pl)
HR (1) HRP20100122T1 (pl)
IL (1) IL189897A0 (pl)
JO (1) JO2578B1 (pl)
MA (1) MA29816B1 (pl)
MX (1) MX2008003173A (pl)
NO (1) NO20081160L (pl)
NZ (1) NZ566345A (pl)
PE (1) PE20070518A1 (pl)
PL (1) PL1937671T3 (pl)
PT (1) PT1937671E (pl)
SI (1) SI1937671T1 (pl)
TW (1) TW200800967A (pl)
WO (1) WO2007030361A2 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007139795A1 (en) * 2006-05-23 2007-12-06 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
JP2009539771A (ja) * 2006-06-02 2009-11-19 スミスクライン ビーチャム コーポレーション 置換ベンゾイミダゾールチオフェンベンジルエーテル化合物
EP2032563B1 (en) * 2006-06-02 2010-06-02 GlaxoSmithKline LLC Benzimidazol substituted thiophene derivatives with activity on plk
US7615643B2 (en) 2006-06-02 2009-11-10 Smithkline Beecham Corporation Benzimidazole thiophene compounds
EP2123627B1 (en) * 2007-01-19 2013-11-20 Ube Industries, Ltd. Process for producing aromatic amine having aralkyloxy or heteroaralkyloxy group
EP2170871A2 (en) * 2007-06-26 2010-04-07 GlaxoSmithKline LLC Processes for preparing benzimidazole thiophenes
WO2009003911A1 (en) * 2007-06-29 2009-01-08 4Sc Ag Thiophene-imidazopyridines
EP2100894A1 (en) 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
WO2009151914A1 (en) * 2008-05-27 2009-12-17 Smithkline Beecham Corporation Methods for treating neoplasms with a combination of a plk inhibitor and retinoid
WO2009154645A1 (en) * 2008-06-20 2009-12-23 Smithkline Beecham Corporation Methods for the treatment of central nervous system tumors
WO2010121675A2 (en) * 2008-12-18 2010-10-28 F. Hoffmann-La Roche Ag Thiazolyl-benzimidazoles
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
NZ599830A (en) 2009-11-05 2014-08-29 Rhizen Pharmaceuticals Sa Novel kinase modulators
PH12013502240B1 (en) 2011-05-04 2018-06-27 Rhizen Pharmaceuticals Sa Novel compounds as modulators of protein kinase
RS56494B1 (sr) 2012-07-04 2018-01-31 Rhizen Pharmaceuticals S A Selektivni inhibitori pi3k delta
KR20210122163A (ko) * 2020-03-27 2021-10-08 (주) 업테라 Plk1의 선택적 분해를 유도하는 피라졸로퀴나졸린 유도체 화합물
KR102574152B1 (ko) * 2020-03-27 2023-09-05 (주) 업테라 Plk1의 선택적 분해를 유도하는 벤즈이미다졸 티오펜 유도체 화합물
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990146A (en) * 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
CA2341409A1 (en) 1998-08-31 2000-03-09 Merck And Co., Inc. Novel angiogenesis inhibitors
BR0313160A (pt) 2002-08-08 2005-07-12 Smithkline Beecham Corp Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
AU2003903440A0 (en) * 2003-07-04 2003-07-17 James Hardie International Finance B.V. Rainscreen apparatus and method
EP1685128A1 (en) * 2003-10-16 2006-08-02 Smithkline Beecham Corporation Process for preparing benzimidazole thiophenes
WO2005037627A1 (ja) 2003-10-20 2005-04-28 Nsk Ltd. ステアリング装置
GB0402809D0 (en) 2004-02-09 2004-03-10 Glaxo Group Ltd Chemical compounds
MX2008003172A (es) * 2005-09-06 2008-03-18 Smithkline Beecham Corp Proceso regioselectivo para la preparacion de bencimidazol-tiofenos.
US20080214563A1 (en) * 2005-09-06 2008-09-04 Mui Cheung Benzimidazole Thiophene Compounds As Plk Modulators
EP2474546A1 (en) 2006-01-23 2012-07-11 Vertex Pharmaceuticals Inc. Thiophene-carboxamides useful as inhibitors of protein kinases
EP2032563B1 (en) * 2006-06-02 2010-06-02 GlaxoSmithKline LLC Benzimidazol substituted thiophene derivatives with activity on plk
JP2009539771A (ja) * 2006-06-02 2009-11-19 スミスクライン ビーチャム コーポレーション 置換ベンゾイミダゾールチオフェンベンジルエーテル化合物

Also Published As

Publication number Publication date
AU2006287766B2 (en) 2010-06-24
AU2006287766A1 (en) 2007-03-15
BRPI0615668A2 (pt) 2011-05-24
PE20070518A1 (es) 2007-06-12
ATE452132T1 (de) 2010-01-15
AR055616A1 (es) 2007-08-29
CA2621879A1 (en) 2007-03-15
KR20080047585A (ko) 2008-05-29
WO2007030361A2 (en) 2007-03-15
EA200800546A1 (ru) 2008-08-29
DE602006011192D1 (de) 2010-01-28
US7786127B2 (en) 2010-08-31
TW200800967A (en) 2008-01-01
DK1937671T3 (da) 2010-04-26
US20070270437A1 (en) 2007-11-22
HRP20100122T1 (hr) 2010-05-31
JP5002597B2 (ja) 2012-08-15
JP2009508816A (ja) 2009-03-05
EP1937671A2 (en) 2008-07-02
EA014111B1 (ru) 2010-10-29
MA29816B1 (fr) 2008-09-01
US20080214567A1 (en) 2008-09-04
CY1109916T1 (el) 2014-09-10
EP1937671B1 (en) 2009-12-16
NZ566345A (en) 2010-04-30
ES2337929T3 (es) 2010-04-30
NO20081160L (no) 2008-05-29
MX2008003173A (es) 2008-03-18
HK1117504A1 (en) 2009-01-16
US7595330B2 (en) 2009-09-29
PT1937671E (pt) 2010-03-12
IL189897A0 (en) 2008-08-07
JO2578B1 (en) 2011-02-27
SI1937671T1 (sl) 2010-04-30
WO2007030361A3 (en) 2007-05-31
CR9786A (es) 2008-05-22

Similar Documents

Publication Publication Date Title
PL1937671T3 (pl) Związki benzimidazolotiofenowe jako inhibitory plk
ZA200707650B (en) Azolylacylguanidines as ß-secretase inhibitors
IL189194A0 (en) Substituted benzimidazoles as kinase inhibitors
GB0608838D0 (en) Organic compounds
IL196562A0 (en) Organic compounds
GB0606774D0 (en) Organic compounds
GB0603684D0 (en) Organic compounds
IL195158A0 (en) Novel heterocyclic compounds
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
GB0613154D0 (en) Organic Compounds
GB0621203D0 (en) PLK inhibitors
ZA200800506B (en) Substituted benzimidazoles as kinase inhibitors
GB0607945D0 (en) Organic compounds
ZA200802087B (en) Benzimidazole thiophene compounds as PLK inhibitors
EP2068870A4 (en) THIOPHENE COMPOUNDS
GB0609378D0 (en) Organic compounds
GB0601406D0 (en) Organic Compounds
GB0601031D0 (en) Organic compounds
IL192928A0 (en) Organic compounds
GB0609268D0 (en) Organic compounds
GB0602123D0 (en) Organic compounds
GB0601951D0 (en) Organic compounds
GB0606804D0 (en) Organic Compounds
GB0704800D0 (en) Lumo level
GB0611064D0 (en) Organic compounds